Specify a stock or a cryptocurrency in the search bar to get a summary
N4 Pharma PLC
N4PN4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom. Address: 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Analytics
WallStreet Target Price
927.09 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures N4P
Dividend Analytics N4P
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History N4P
Stock Valuation N4P
Financials N4P
Results | 2019 | Dynamics |